A revised price target for Invesco Mortgage Capital (IVR) is prompting investors to reassess the mortgage REIT's trajectory amid evolving interest rate expectations and housing market dynamics.
Bitmine Immersion Technologies faces heightened scrutiny following the sudden departure of its president and a strategic pivot that has seen it amass over 3.5% of all Ethereum. Analysts question the dual risks of management instability and extreme asset concentration as the stock shows recent volatility.
Shares in Canadian aerospace giant Bombardier plunged 9% following former U.S. President Donald Trump's threat to impose 50% tariffs and decertify its aircraft, escalating trade tensions and sparking alarm across the North American aviation industry.
President Donald Trump's nomination of Kevin Warsh to lead the Federal Reserve sets the stage for a potential pivot in U.S. monetary policy, placing a seasoned yet controversial figure with deep Wall Street ties at the helm.
Despite posting robust quarterly earnings, Microsoft shares tumbled over 10% as investors balked at rising costs and a cautious outlook, raising questions about the sustainability of its AI-driven growth narrative.
While mortgage rates have inched up slightly this week, homebuyers are still facing significantly lower borrowing costs compared to last year's peak. We break down the monthly and long-term savings on a typical home purchase.
Exclusive footage and soldier testimonies reveal a disturbing pattern within Russian ranks: wounded amputees, including former prisoners, are being ordered back into combat as casualties mount and manpower dwindles.
Denmark's government announced a bold legislative package aimed at expanding deportations and tightening immigration controls, setting the stage for a potential clash with the European Court of Human Rights.
Secretary-General Antonio Guterres warns in a confidential letter that the United Nations faces a severe cash crunch, driven by unpaid dues and restrictive budget rules, threatening its operational viability by mid-year.
Brazilian President Luiz Inácio Lula da Silva was released from a São Paulo hospital Friday following a planned cataract procedure on his left eye, with his office confirming a swift return to official duties next week.
With the specter of U.S. military action looming, Iran is engaging in a frantic diplomatic push with regional powers like Turkey, while global capitals scramble to prevent a full-scale war. Despite the outreach, analysts warn the window for de-escalation is narrowing.
The NBA's Minnesota Timberwolves have released a public statement calling for community solidarity following two separate fatal shootings involving federal immigration agents in Minneapolis, which have sparked protests and renewed debate over immigration enforcement.
As hearings conclude at the UN's highest court, Rohingya refugees express cautious hope for a landmark genocide ruling against Myanmar, a decision with potential global legal ramifications.
The Kremlin confirmed Friday that President Vladimir Putin has agreed to a week-long pause in strikes on the Ukrainian capital Kyiv, a move initiated by a personal request from U.S. President Donald Trump. The temporary ceasefire, set to expire Sunday, comes amid a brutal cold snap and ahead of a new round of negotiations.
Bank of America has increased its price target for industrial packaging firm Greif (GEF) by $1 to $75, while reiterating a Neutral rating. The adjustment follows the bank's broader reassessment of the packaging sector after recent quarterly earnings calls.
Analysts at Truist reaffirm their Buy rating on DLocal (DLO), raising their price target to $17 ahead of the fintech firm's Q4 2025 earnings. While expecting solid results, they flag challenging year-over-year volume comparisons that may cap upside surprises.
Rosenblatt Securities initiates coverage on Credo Technology with a Neutral rating and a $170 price target, highlighting its strong position in high-speed connectivity for AI infrastructure while flagging competitive pressures. The note follows a more bullish target hike from Barclays earlier in the month.
Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
B.Riley initiates coverage on BrightSpire Capital (BRSP) with a Buy rating, highlighting its robust cash position and improved credit quality as key drivers for future loan originations, while its stock trades at a discount to book value.
